SAVA - CASSAVA SCIENCES INC
2.03
-0.010 -0.493%
Share volume: 676,814
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.14%
PREVIOUS CLOSE
CHG
CHG%
$2.04
-0.01
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-10-2024 | 08-08-2024 | 11-07-2024 | 03-03-2025 | 05-08-2025 | 08-14-2025 | 11-12-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 19.934 M | 61.402 M | 30.623 M | 29.487 M | 24.586 M | 45.392 M | 11.860 M | |
| Selling general and admin | 3.701 M | 46.204 M | 12.947 M | 8.957 M | 10.920 M | 40.276 M | 7.905 M | |
| Research and development | 16.233 M | 15.198 M | 17.676 M | 20.530 M | 13.666 M | 5.116 M | 3.955 M | |
| Total expenses | 19.934 M | 61.402 M | 30.623 M | 29.487 M | 24.586 M | 45.392 M | 11.860 M | |
| 208.03% | -50.13% | -3.71% | -16.62% | 84.63% | -73.87% | |||
| Operating income | -19.934 M | -61.402 M | -30.623 M | -29.487 M | -24.586 M | -45.392 M | -11.860 M | |
| Ebit | 23.267 M | 3.740 M | -30.623 M | -29.236 M | -24.586 M | -45.392 M | -11.860 M | |
| Pretax income | 25.043 M | 6.056 M | -28.005 M | -35.946 M | -23.321 M | -44.178 M | -10.693 M | |
| -75.82% | -562.43% | 28.36% | -35.12% | 89.43% | -75.80% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | 25.043 M | 6.155 M | -27.943 M | -27.597 M | -23.403 M | -44.224 M | -10.807 M | |
| -75.42% | -553.99% | 1.24% | 15.20% | -88.97% | 75.56% |